Today's Date: May 6, 2021
DreamStart Labs Wins Fast Company "World Changing Idea" Awards in Four Categories Including Best Developing World Technology   •   Fund for Teachers Announces 2021 Fellows and Innovation Grant Recipients   •   Government of Canada COVID-19 Update for Indigenous Peoples and communities   •   Travel + Leisure Group Launches Brand Licensing Business   •   Regis Reports Third Quarter 2021 Improved Traffic Trends and Continued Progress in Key Initiatives   •   Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govi   •   Show You Love Her With All Your Heart: Serena Williams Introduces a New Jewelry Design Motif   •   Plymouth Rock Assurance and the UB Alumni Association Introduce New Affinity Discount Program   •   Eleven Women Accuse Eastern Michigan University of Covering Up Sexual Assault Claims, Reports A Case for Women   •   AJC's Engagement with the Arab World Reaches New Heights   •   FRC Celebrates Growing Momentum for Protection of the Unborn from Discrimination on the Basis of Race, Sex, or Disability   •   Sarasota's Newest Community for Active Senior Living is Open for Pre-Leasing   •   Jam City and Fremantle Partner to Bring Family Feud™ to Cookie Jam   •   Delta Israel Brands Ltd. Publishes Its First Financial Statement, for Q1 2021, and Shows Significant Growth   •   Cymbiotika Introduces Rya Organics for Its Market-leading CBD Products   •   Civil-Military Innovation Institute expands to Research Triangle Park   •   Diligent’s Modern Leadership Initiative Adds New Partners to Provide Greater Visibility to Women Who Are Board-Ready   •   Greenberg Traurig Assists San Manuel Band of Mission Indians to Acquire Palms Casinos Resort   •   Budget investments will strengthen Indigenous communities   •   Humana Foundation Invests 5.4 Million in Eight Communities to Address Social Determinants of Health
Bookmark and Share

Blacks Benefiting From Targeted Cancer Therapy

 PHILDALPHIA — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

“This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not,” said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer Institute, and assistant professor at Wayne State University School of Medicine.

Haddad’s study, which he presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, also showed that African-Americans were more likely to have mutations on exon 19, rather than exon 21, which suggests they would be even more responsive to erlotinib.

Erlotinib, currently marketed as Tarceva by Genentech, has shown remarkable benefits in non-small cell lung cancer patients with EGFR mutations. Other therapies are in development and the genetic testing is clinically available.

Previous studies had suggested that African-Americans had lower rates of EGFR mutation, which researchers had offered as a possible explanation for their generally poorer prognosis.

However, Haddad’s study was larger than previous reports. His research team observed 149 patients with non-small cell lung cancer (NSCLC), including 80 Caucasians and 69 African-Americans.

Using state-of-the-art technology that allowed for simultaneous detection of hundreds of oncogene mutations in clinical samples, they identified EGFR mutations in 20 of these patients, including 12 Caucasians and eight African-Americans. The difference was not statistically significant.

Moreover, 100 percent of the EGFR mutations in African-Americans were in exon 19, compared with only two-thirds of the mutations found in Caucasian patients. 

“It is well-documented that the incidence of lung cancer is higher among African-Americans, particularly men, and that their survival is generally poorer compared to their white counterparts,” said Haddad. “Our data suggest that African-Americans with NSCLC harbor mutations in EGFR at rates similar to whites. Thus, African ancestry should not be a factor when deciding whether to test a tumor for these mutations, as doing so could widen the disparity seen in survival. Physicians treating these patients may want to consider this new information in their treatment decisions.” 

 


STORY TAGS: BLACK , AFRICAN AMERICAN , MINORITY , CIVIL RIGHTS , DISCRIMINATION , RACISM , NAACP , URBAN LEAGUE , RACIAL EQUALITY , BIAS , EQUALITY

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News